Experimental Hematology
Volume 36, Issue 5 , Pages 535-544, May 2008

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

  • Mauricette Michallet

      Affiliations

    • Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
    • Drs. Michallet and Mohty contributed equally to this study.
  • ,
  • Quoc-Hung Le

      Affiliations

    • Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
  • ,
  • Mohamad Mohty

      Affiliations

    • Hôpital Hôtel-Dieu, CHU de Nantes, Nantes, France
    • Drs. Michallet and Mohty contributed equally to this study.
    • Corresponding Author InformationOffprint requests to: Mohamad. Mohty, M.D., Ph.D., Hématologie Clinique, Université de Nantes-INSERM UMR U601, CHU Hôtel-Dieu, Place Alexis Ricordeau, F-44093 Nantes Cedex 01, France
  • ,
  • Thomas Prébet

      Affiliations

    • Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
    • Dr. Prébet is currently at the Département d'Hématologie, Institut Paoli-Calmettes, Marseille, France.
  • ,
  • Franck Nicolini

      Affiliations

    • Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France
  • ,
  • Jean Michel Boiron

      Affiliations

    • Service d'Hématologie Hôpital Pessac, Bordeaux, France
    • Dr. Boiron is currently at EFS de Bordeaux, Bordeaux, France.
  • ,
  • Hélène Esperou

      Affiliations

    • Unité de Greffe de Moelle Osseuse, Hôpital St Louis, Paris, France
  • ,
  • Michel Attal

      Affiliations

    • Service d'Hématologie, Hôpital Purpan, Toulouse, France
  • ,
  • Noel Milpied

      Affiliations

    • Hôpital Hôtel-Dieu, CHU de Nantes, Nantes, France
    • Dr. Milpied is currently at Service d'Hématologie Hôpital Pessac, Bordeaux, France.
  • ,
  • Bruno Lioure

      Affiliations

    • Service d'Hématologie, Hôpital Hautepierre, Strasbourg, France
  • ,
  • Pierre Bordigoni

      Affiliations

    • Service d'Hématologie, Hôpital Nancy, Nancy, France
  • ,
  • Ibrahim Yakoub-Agha

      Affiliations

    • Service d'Hématologie, Hôpital Huriez, Lille, France
  • ,
  • Jean-Henri Bourhis

      Affiliations

    • Service d'Hématologie, Institut Gustave Roussy, Villejuif, France
  • ,
  • Bernard Rio

      Affiliations

    • Service d'Hématologie, Hôpital Hotel Dieu, Paris, France
  • ,
  • Eric Deconinck

      Affiliations

    • Service d'Hématologie, Hôpital Besançon, Besançon, France
  • ,
  • Marc Renaud

      Affiliations

    • Service d'Hématologie, Hôpital Poitiers, Poitiers, France
  • ,
  • Zina Chir

      Affiliations

    • Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Agence de Biomédecine, Paris, France
  • ,
  • Didier Blaise

      Affiliations

    • Institut Paoli-Calmettes, Marseille, France

Received 8 September 2007; received in revised form 3 January 2008; accepted 11 January 2008. published online 17 March 2008.

This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Société Française de Greffe de Moelle et de Thérapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including >10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(08)00053-2

doi:10.1016/j.exphem.2008.01.017

Experimental Hematology
Volume 36, Issue 5 , Pages 535-544, May 2008